The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

However, the machines tend to be ... May 30, 2024 — A new study demonstrates that when individuals with obstructive sleep apnea use their positive airway pressure machine more regularly ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...